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Interleukin-33 (IL-33) is a recently identified cytokine, an important member of the
interleukin-1 family. IL-33 binds to its receptor ST2 to induce type 2 cytokines and exert both
pro-inflammatory and protective functions in host defense and disease. Murine breast car-
cinoma models suggest disruption of ST2 signaling may enhance the anti-tumor immune
response, suggesting IL-33 impedes anti-tumor immunity. However, the role of IL-33 in
patients with breast cancers (BC) is not elucidated. We detected the expression of IL-33 in
tumor tissue, and IL-33 and its related cytokines in serum from BC patients. Using Luminex
and immunohistochemistry methods, we found that serum levels of IL-33 were nearly
twofold higher in patients with BC, compared to patients with benign breast diseases. In
cancer tissues, expression of IL-33 was higher than matched normal breast tissues from
the same patients, and was also associated with a well-differentiated phenotype, HER2
overexpression, more lymph nodes involvement, and a family history of malignant carci-
noma. These results suggest that IL-33 may play an important role in the progress of BC
and may be a useful biomarker for predicting the progress and metastasis of BC.
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INTRODUCTION
Breast cancer (BC) is the second leading cause of cancer-related
deaths amongst women in the United States, and morbidity and
mortality of this disease increases each year (1). Although stan-
dard multi-modality treatment has improved the overall out-
come and quality of life for patients with BC, identification of
new prognostic markers, therapeutic targets, and new therapeutic
approaches are needed. Recent insights into the cancer develop-
ment mechanisms have revealed that immune system functionally
regulates development and progression of epithelial malignancies
and tumor-infiltrating leukocytes may be causal players in cancer
development (2).
The interleukin-1 (IL-1) family is a growing group of cytokines,
consisting of at least 11 members, and the balance between pro-
and anti-inflammatory cytokines is crucial in the pathogenesis of
many human diseases (3). Interleukin-33 (IL-33) is an important
member of the IL-1 family, and in humans is expressed predomi-
nantly in skin, lung, adipocytes, and synovial fibroblasts (4). IL-33
is an endogenous ligand for the ST2/T1 receptor, and depending
on the cellular and cytokine context, participates in many immune
diseases with dual, pro-inflammatory, or protective roles. IL-33
induces T cells to produce IL-4, IL-5, and IL-13, and potently
induces pro-inflammatory cytokines and chemokines through a
Th2-dependent pathway, and also promotes Th1-type responses
(5). IL-33 is involved in the pathogenesis of immune diseases, such
as rheumatoid arthritis and atopic dermatitis, and may reflect
the degree of inflammation in patients with immune diseases
(6, 7). Deletion of IL-33/ST2 function enhances cytotoxicity of
NK cells and increases levels of TNF-α, IFN-γ, and IL-17, and
systemic pro-inflammatory cytokines, leading to attenuated tumor
growth (8).
Recent studies demonstrated that high serum levels of soluble
ST2 (sST2) are a worse prognostic factor in hepatocellular car-
cinoma (9), and that serum IL-33 is a diagnostic and prognostic
marker in non-small cell lung cancer, independent of the therapeu-
tic intervention (10). In studies on mouse mammary carcinoma,
the IL-33/ST2 pathway promotes BC progression and metastasis
through increased intratumoral accumulation of immunosup-
pressive cells and by diminishing innate anti-tumor immunity
(11). Conversely, Gao et al. reported that transgenic expression
of IL-33 may activate CD8(+) T cells and NK cells, and inhibit
tumor growth and metastasis in B16 melanoma and Lewis lung
carcinoma metastatic models (12). Thus, the data on the role of
IL-33 in cancer progression was limited, and in particular, the
function mediated by IL-33 in human BC is under-investigated.
In this study, we aim to determine the serum level and to detect
the expression of IL-33 in human tissues in patients with breast
carcinoma, using Luminex-based measurements and immunohis-
tochemistry, to further explore the role of IL-33 in anti-tumor
immunity in BC.
MATERIALS AND METHODS
PATIENTS
This study was approved by the Ethics Committee of Shantou Uni-
versity Medical College and conducted according to the principles
in the Declaration of Helsinki (13).
Blood samples were drawn from 64 patients with BC and
10 patients with benign breast diseases (BBD) as controls, who
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visited the Shantou University Medical College Cancer Hospi-
tal Breast Center between April 2013 and July 2013. The mean
age was 52± 11 years (25–80 years old) for patients with BC,
and 41± 11 years (28–68 years old) for patients with BBD. All
patients were pathologically diagnosed using specimens obtained
either by core-needle biopsy or by surgery. The clinicopathological
characters of the BC patients are summarized in Table 1.
The central regions of tumors were collected from 29 BC
patients, as well as microscopic normal tissues from either tumor-
adjacent normal tissue (<1 cm) or normal tissue≥5 cm away from
the tumor margins, for which paraffin-embedded samples were
available. The mean age was 53± 13 years (25–80 years old) for all
enrolled patient. The clinicopathological characteristics of the 29
BC patients are summarized in Table 3.
ASSESSMENT OF SERUM CYTOKINES
The levels of IL-33, IL-12, IL-13, IL-17, IFN-γ, and TNF-α in serum
were measured based on a Luminex assay, using Milliplex™ MAP
(Millipore, MA, USA) multiplex magnetic bead-based antibody
detection kits according to the manufacturer’s protocols (14).
Blood from patients was collected and centrifuged for 10 min
at room temperature. Serum was removed carefully and stored
at −80°C until use. Twenty-five microliters of neat samples were
added into each well of 96-well plate, and then 25µl mixed beads
were added to the samples. The plate was incubated with agitation
on a plate shaker overnight at 4°C. Twenty-five microliters of anti-
cytokine antibody was then added and incubated for 1 h at room
temperature. Lastly, 25µl streptavidin–phycoerythrin was added
into each well containing the detection antibodies for 30 min at
room temperature. Cytokines were quantified using a BioPlex 200
platform (BioRad, CA, USA).
IMMUNOHISTOCHEMISTRY
Surgical specimens of cancer tissues, adjacent tissues to tumors,
and normal tissues collected from patients with BC were
formalin-fixed, paraffin-embedded, and cut into four-micron-
thick sections. Sections were deparaffinized by immersion in
xylene, and rehydrated in a series of graded alcohols. Epitope
retrieval and inactivation of endogenous peroxidase activity was
achieved as described (15). Samples were incubated overnight
at 4°C with anti-IL-33 (R&D Systems, Minneapolis, MN, USA),
then visualized using 3,3′-diaminobenzidine tetrahydrochloride
(DAB). Sections without primary antibody were used as neg-
ative controls. Counterstaining was carried out with hema-
toxylin, and sections were visualized and photographed under
a bright-field microscope (Olympus, Tokyo, Japan). Immuno-
histochemical staining was mainly cytoplasmic, and the per-
centage of positive cells for IL-33 was calculated for analy-
sis by counting at least 200 cells in five or more high power
fields.
Estrogen receptor (ER) and progesterone receptor (PR) were
interpreted as negative or positive, if equal to and less than 1% or
more than 1% of tumor showed nuclear positivity, respectively.
HER2 was interpreted as negative or over-expressed, if there was
0–1+ or 3+ membranous staining, respectively. If there was 2+
membranous staining, FISH was conducted to determine whether
HER2 was over-expressed (16). A Ki-67 cut-off point of 15% was
Table 1 | Relationship of serum IL-33 levels with clinicopathological
parameters of breast cancer patients.
Variables IL-33 level (pg/ml)
N Mean SD P value
Age
≤50 years 30 35.87 11.00 0.481
>50 years 34 38.21 14.78
Menopausal statusa
No 33 36.19 11.33 0.992
Yes 30 36.52 12.26
Size
≤2 cm 26 36.50 11.52 0.760
>2 cm 38 37.53 14.21
AJCC stage
I+ II 44 37.93 12.11 0.465
III 20 35.32 15.23
Histological gradeb
1+2 30 36.51 13.58 0.915
3 23 36.14 10.64
ER expressionc
Negative 26 32.79 10.84 0.033
Positive 37 39.92 13.97
PR expressionc
Negative 32 36.76 16.28 0.896
Positive 31 37.20 9.17
HER2 expressionc
No 46 37.82 14.28 0.409
Yes 17 34.71 9.48
Ki-67 expressionc
Low 15 43.74 19.40 0.021
High 48 34.86 9.86
Lymph node metastasis
≤3 56 37.59 13.52 0.445
>3 8 33.78 9.67
Family history
No 58 36.00 11.69 0.034
Yes 6 47.81 21.29
aOne case missing this information because the patient was male.
bTwo cases with invasive lobular carcinomas, one case with an intraductal papil-
lary carcinoma, and in eight cases, only biopsy samples were available without
information on histological grade.
cOne case was discharged after biopsy, without information on ER, PR, HER2,
and Ki-67 expression.
defined according to the experience of different pathologists as well
as national and international recommendations at present (17).
STATISTICAL ANALYSIS
Serum levels and tissue expression are expressed as the
mean± standard deviation (SD). Differences between groups
were analyzed using the Student t-test or the non-parametric
Mann–Whitney test. All statistical differences were considered sig-
nificant at the level of p< 0.05. All data were analyzed with SPSS
19.0 software for Windows.
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RESULTS
SERUM LEVELS OF IL-33 AND RELATED CYTOKINES IN BBD AND BC
Among six cytokines, the concentrations of IL-33 were nearly
twofold higher in the BC group (34.49± 1.65 pg/ml) compared
with BBD group (17.71± 2.60 pg/ml) (p= 0.0008), with a non-
normal distribution (Figure 1A). Conversely, serum levels of
IL-13, a Th2-associated cytokine, in the BC group (14.79± 0.45)
were 40% lower than in the BBD group (24.92± 8.68 pg/ml)
with borderline difference (p= 0.0608) (Figure 1B), and the
concentrations of IL-12, a Th1-type cytokine, were 35% lower
in the BC group (6.143± 0.25 pg/ml) than in the BBD group
(9.39± 2.11 pg/ml) with statistical significance (p= 0.0178)
(Figure 1C). The concentrations of other cytokines, IL-17, TNF-
α, and IFN-γ, did not show any significant difference between the
BBD and BC groups (p> 0.05, Figures 1D–F).
CLINICOPATHOLOGICAL ANALYSIS OF SERUM LEVELS OF IL-33 IN
BREAST CARCINOMA PATIENTS
In patients with ER-positive breast tumors, the serum lev-
els of IL-33 were 39.92± 13.97 pg/ml, and were significantly
higher than in patients with ER-negative tumors, which were
32.79± 10.84 pg/ml, p= 0.033 (Table 1). In patients who showed
lower Ki-67 expression, the serum levels of IL-33 were higher
than the high Ki-67-expressing group (43.74± 19.40 pg/ml vs.
34.86± 9.86 pg/ml, p= 0.021). The serum concentrations of IL-
33 were significantly associated with family history of malig-
nant tumors (p= 0.034). No correlation was observed between
serum IL-33 levels and patient age, menopausal status, tumor size,
AJCC stage, histological grade, lymph node status, PR, and HER2
expression.
We also analyzed the association of clinicopathological para-
meters with IL-33-related cytokines. The serum levels of INF-γ
were associated with tumor size (p= 0.039), with INF-γ being
higher in patients with tumors<2 cm in size (22.57± 2.63 pg/ml)
than patients with tumors >2 cm (15.22± 5.13 pg/ml). In pre-
menopausal patients, the serum levels of IL-17 were signifi-
cantly higher (p= 0.048) than that in post-menopausal group
(15.51± 6.29 vs. 13.13± 2.16 pg/ml), and serum levels of IL-17
were also significantly associated with AJCC stage (p= 0.049)
and HER2 expression (p= 0.012). No statistical significance was
FIGURE 1 | Interleukin-33 and associated cytokine levels in benign breast
diseases (BBD) and breast cancers (BC). (A) Serum IL-33 expression in BC
was significant higher than that in BBD (p=0.0008); (B) no significant
difference between serum IL-13 expression in BC and BBD (p=0.0608);
(C) serum IL-12 expression in BBD was significant higher than that in BC
(p=0.0178); (D) no significant difference between serum IL-17 expression in
BC and BBD (p=0.0526); (E) no significant difference between serum TNF-α
expression in BC and BBD (p=0.9748); (F) no significant difference between
serum IFN-γ expression in BC and BBD (p=0.7693); *p<0.05 by unpaired
two tailed Student’s t-test.
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found between the serum levels of TNF-α, IL-12, or IL-13 with
clinicopathological parameters of BC patients (specific data not
shown).
IL-33 IS HIGHER IN CANCER TISSUES, COMPARED WITH ADJACENT
AND NORMAL TISSUES
Figure 2 shows a representative immunohistochemical staining of
IL-33 in tissues from patients with BC. In 29 patients with BC,
mean expression of IL-33 in carcinoma was 72.6% of cells in the
tumor, which was significantly higher than in normal breast tis-
sues from the same patients (p< 0.0001) as shown in Table 2.
Interestingly, the mean expression of IL-33 in adjacent tissues to
tumor was 64.1%, which was also significantly higher than in nor-
mal breast tissues from the same patients (p= 0.0002). However,
the mean expression level of IL-33 was not statistically different
between in cancer and adjacent tissues (p= 0.3561).
CLINICOPATHOLOGICAL ANALYSIS OF CYTOPLASMIC IL-33
EXPRESSION IN BREAST CANCER TISSUES
Interleukin-33 was mainly detected in cytoplasm of BC cells as
shown in Figure 2. With quantitative analysis, mean expres-
sions of IL-33 were not significantly associated with the age
at diagnosis, menopausal status, tumor size, AJCC stage, ER,
PR, and Ki-67 expression (Table 3). In comparison with high
grade tumors, low grade tumors showed significant higher IL-
33 expression (p= 0.027). Interestingly, high IL-33 expression
was more frequently observed in tumors with HER2 overexpres-
sion (p= 0.017). In patients with more than three lymph nodes
involved, the expression of IL-33 was significantly higher than
the patients with ≤3 metastases (p= 0.002). High IL-33 expres-
sion was also associated with family history of malignant tumor
(p= 0.002).
DISCUSSION
Interleukin-33, the newest member of IL-1 family, is a recently
identified cytokine with diverse and context-dependent functions,
and has been shown to bind to ST2. IL-33 has also been charac-
terized as a potent inducer of T helper (Th) 2 immune responses,
and is an important mediator for mucosal healing and epithelial
Table 2 |The percentage of IL-33-positive tissue in breast tumors,
tumor-adjacent tissues, and normal tissues from breast cancer
patients.
Samples IL-33 (%)
N Mean SD P valuea
Breast carcinoma tissue 29 72.6 34.5 <0.0001
Adjacent tissues to tumors 29 64.1 34.7 0.0002
Normal breast tissues from BC patients 25b 26.8 33.0
BC, breast cancer.
aStatistically significantly different was found between cancer tissues vs. normal
breast tissues, and between adjacent tissues vs. normal breast tissues from BC
patients, using unpaired Student’s t-test. No statistical significance was found
between cancer tissues and adjacent tissues.
bIn four cases, no normal breast tissues were available.
FIGURE 2 | Immunohistochemical staining of IL-33 in patients with
breast cancers. Representative images of immunohistochemical staining for
IL-33 in breast carcinoma, adjacent tissue to tumor, and normal tissue.
(A) High IL-33 expression in carcinoma tissues. (B) IL-33 expression in tissue
adjacent to tumors. (C) Low IL-33 expression in carcinoma tissue. (D) IL-33
expression in normal breast tissue from BC patients (magnification: ×400).
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Table 3 | Clinicopathological analysis of cytoplasmic IL-33 expression
in breast carcinoma.
Variables IL-33 (%)
N Mean SD P value
Age
≤50 years 13 83.85 27.25 0.103
>50 years 16 63.44 37.71
Menopausal status
No 13 83.85 27.25 0.114
Yes 16 63.44 37.72
Size
≤2 cm 13 68.85 32.28 0.607
>2 cm 16 75.63 36.87
AJCC stage
I+ II 22 69.09 34.21 0.342
III 7 83.57 35.44
Histological gradea
1+2 15 87.33 18.70 0.027
3 11 58.64 41.96
ER expression
Negative 14 76.8 34.8 0.536
Positive 15 68.7 34.82
PR expression
Negative 16 73.44 34.09 0.887
Positive 13 71.54 36.25
HER2 expression
No 18 62.50 38.90 0.017
Yes 11 89.09 16.40
Ki-67 expression
Low 6 75.00 24.29 0.851
High 23 71.96 37.07
Lymph node metastasis
≤3 24 67.71 35.87 0.002
>3 5 96.00 8.94
Family history
No 26 69.81 35.34 0.002
Yes 3 96.67 5.77
aTwo cases with invasive lobular carcinomas and one case with an intraductal
papillary carcinoma.
restoration/repair (18). IL-33/ST2 axis can also promote Th1-type
responses depending on the presence or absence of IL-12 (5). The
influence of the IL-33/ST2 axis may be protective or pathogenic
in various disease conditions, as it has a dual role in inflamma-
tory disorders (8, 19). IL-33 plays a crucial role in inflammation
and is associated with many diseases, such as giant cell arteritis
(20), biliary atresia (21), and chronic obstructive lung disease (22).
However, few data have been reported about the role of IL-33/ST2
axis in cancer, and little is known about the function of IL-33 in
patients with BC.
In this study, we investigated the serum level and tissue expres-
sion of IL-33 in patients with BC. We found significantly higher
serum levels of IL-33 in patients with BC, compared with patients
with BBD, and higher expression of IL-33 in carcinomas and adja-
cent tissues to tumors, compared with normal breast tissue from
the same patients.
The serum concentration of sST2, the soluble form of the recep-
tor for both IL-33 and IL-1, has been shown to be elevated in
patients with metastatic BC, and knockdown of the sST2 decreases
ErbB2-induced cell motility in two different cell lines (23). How-
ever, there are no previous reports about IL-33 expression in serum
or tissues of BC patients. In this study, serum levels of IL-33 are
higher in patients with ER-positive tumors, predicting that the
IL-33/ST2 axis may be involved in hormone receptor signaling.
Moreover, in carcinoma tissues, IL-33 expression is significantly
higher in HER2-overexpressing tissues, consistent with the report
that its receptor sST2 is over-expressed to promote BC metastases
upon ErbB2 activation in BC cell lines (23). In ST knock out mice
models, lack of ST2 can suppress BC progression and metasta-
sis, through enhanced cytotoxic activity of NK cells and increased
systemic Th1/Th17 cytokines (24). Although we found no asso-
ciation between serum levels of IL-33 and in patients with more
than three involved lymph nodes, the higher expression of IL-33
consistent with the IL-33/ST2 axis being involved in progression
and metastasis of BC.
Of interest is that serum levels and carcinoma tissue expression
of IL-33 are higher in patients with a family history of malig-
nant breast carcinoma. As IL-33 may play an important role in
immunosuppression of cancer for subsequent tumor progression
and metastasis, and auto-immune diseases are usually hereditary,
patients with a family history may be more likely to trigger or
promote the process of immunosuppression (11). Whether and
how IL-33 expression is linked auto-immune disease and familial
cancers needs to be clarified.
Ki-67 is a cancer cell proliferation biomarker (25). IL-33 was
higher in the low Ki-67 expression group, suggesting serum lev-
els of IL-33 are negatively associated with BC proliferation. After
analyzing cytokines associated with IL-33, only a decrease in IL-12
is observed in patients with BC, suggesting systemic IL-33 may
not play an important role in BC immunity. In a murine model,
the IL-33/ST2 axis has been demonstrated to facilitate intratu-
moral accumulation of immunosuppressive and innate lymphoid
cells, and then promote BC growth and metastases (11). Similarly,
in head and neck squamous cell carcinomas, administration of
IL-33 promotes cancer cell migration and invasion through induc-
tion of epithelial-to-mesenchymal transition. Moreover, IL-33 has
been shown to be a potential prognostic biomarker and target for
new therapeutic strategies (26). Recent research suggests that in
the breast tumor environment, tumor-infiltrating T lymphocytes
(TILs) secrete IL-17A, to activate the MAPK pathway, promot-
ing proliferation and resistance to conventional chemotherapeu-
tic agents (27). The elevations of both IL-33 serum levels and
immunohistochemical expression might promote BC progression
and metastases through regulation of IL-12 pathway.
The local expression of IL-33 may be an important marker
for differentiating malignant from normal/benign tissues. IL-33
expression in adjacent tissues also tends to be higher compared
to normal tissues, suggesting that adjacent non-cancerous tis-
sues may be similarly relevant to cancers in terms of anti-tumor
immunity. Local IL-33 expression may also increase intratumoral
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accumulation of immunosuppressive lymphoid cells in patients
with BC. However, in high grade tumor tissue, the expression of
IL-33 is decreased compared to low grade tumor tissues, indicat-
ing that IL-33 may be more important in HER2-over-expressing
tumors, and other cytokines may be involved in this crosstalk of
regulation. Interestingly, IL-33 expression in serum and cancer tis-
sues was contrary when comparing with ER and HER2 expression,
although with statistical significance (Tables 1 and 3). Up to now,
there were no reports about the relationship between IL-33 and
ER or HER2. So we supposed that IL-33 may play different roles
in system and in local tissues under different hormone conditions.
The IL-33 may be involved in the resistence to endocrine therapy
and Herceptin therapy of ER/HER2 positive patients with BC.
It is confirmed that IL-33 could activate, Th1, NK, NKT, and
CD8+ T cells under certain pathophysiological conditions (11).
On the other hand, IL-33 has a dual role in inflammatory disor-
ders, anti- and pro-inflammatory. The tissue expression of IL-33 is
significantly different, indicated that in carcinomas, immune cells
may be recruited to anti-inflammatory and subsequent immuno-
suppression in HER2 overexpression tumors. In summary, this
study indicated that serum IL-33 is higher in cancer patients
compare to patients with BBD. Immunohistochemical staining
demonstrated that IL-33 is higher in both cancerous and adjacent
tissues compared to normal tissues, suggesting its role in BC pro-
gression and metastases. Thus, IL-33 may be a useful biomarker
for prediction of malignant potential and immunosuppression of
breast carcinomas.
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